

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
	39042-0036	10/579,088
	APPLICANT: Manzer Durrani	
	FILING DATE: 11/11/2004	GROUP: 1646

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,150,071	04-17-79	Pecina			
	4,198,969	04-22-80	Virag			
	4,253,468	03-03-81	Lehmbeck			
	4,301,970	11-24-81	Craighero			
	4,453,542	06-12-84	Hughes			
	4,599,311	07-08-86	Kawasaki			
	4,620,670	11-04-86	Hughes			
	4,732,973	03-22-88	Barr, et al.			
	4,931,373	06-05-90	Kawasaki, et al.			
	5,093,316	03-03-1992	Lezdey, et al.			
	5,134,119	07-28-92	Lezdey, et al.			
	5,150,071	09-22-92	Bouzidi			
	5,166,134	11-24-92	Lezdey, et al.			
	5,218,091	06-08-93	Kawasaki, et al.			
	5,618,786	04-08-97	Roosdorp, et al.			
	4,711,848	12-08-87	Insley, et al.			
	5,780,440	07-14-98	Lezdey, et al.			
	5,993,783	11-30-99	Eljamal, et al.			
	0006939	07-05-01	Niven, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0289 336 A	11-02-88	EP			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO. 39042-0036	SERIAL NO. 10/579,088
		APPLICANT: Manzer Durrani	
		FILING DATE: 11/11/2004	GROUP: 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Carlson, et al., J. Clin. Invest., Vol. 83, pp. 1183-1190, 1989		
	Carrell, et al., Nature, Vol. 298, pp. 329-334, 1982		
	Carter, et al., Nucleic Acids Research, Vol. 13, No. 12, pp. 4431-4443, 1985		
	Development and Manufacture of Protein Pharmaceuticals, Edited by Steven Nail and Michael J. Akers, Pharmaceutical Biotechnology, Vol. 14, Kluwer Academic/Plenum Publishers, pp. 65-66, 2002		
	Dycaico, et al., Science, Vol. 242, No. 4884, pp. 1409-1412, 1988		
	Gadek, et al., The Metabolic Basis of Inherited Disease (Stanbury, J.B. et al., Eds.) McGraw-Hill, New York, pp. 1450-1467, 1982		
	GenBank Accession No. AAB59375		
	Handbook of Pharmaceutical Additives 2 nd Edition, Complied by Michael and Irene Ash, Synapse Information Resources, Inc. pp. 797-798, 2002		
	Hunnighake, et al., Am. Rev. Respir. Dis., Vol. 128, pp. 833-838 1983		
	Lomas, et al., Nature, Vol. 357, pp. 605-607, 1992		
	Neddeleman & Wunsch, J. Mol. Biol., Vol. 48, p. 443-453, 1970		
	Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA, Vol. 85, p. 2444-2448, 1988		
	Practical Approaches to Protein Formulation Development, Byeong Chang and Susan Henderson, Rational Design of Stable Protein Formulations: Theory and Practice, Edited by John F. Carpenter and Mark C. Manning, Pharmaceutical Biotechnology Vol. 13, Kluwer Academic/Plenum Publishers, pp. 1-20, 2002		
EXAMINER	DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39042-0036	SERIAL NO. 10/579,088
	APPLICANT: Manzer Durrani	
	FILING DATE: 11/11/2004	GROUP: 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Smith & Waterman, Adv. Appl. Math., Vol. 2, p. 482, 1981	
	Smith, et al., J. Clin. Invest., Vol. 84, pp. 1145-1154, 1989	
	Surfactant-Protein INteractions, Theodore W. Randolph, LaToya S. Jones, Rational Design of Stable Protein Formulations: Theory and Practice, Edited by John F. Carpenter and Mark C. Manning, Pharmaceutical Biotechnology, Vol. 13, Kluwer Academic/Plenum Publishers, p. 159-171, 2002	
	Wells, et al., Gene, Vol. 34, p. 315-323, 1985	
	Wells, et al., Philos Trans. R. Soc. London SerA, Vol. 317, p. 415-423, 1986	
	Wu, et al., Proc. Natl. Acad. Sci., Vol. 91, pp. 9014-9018, 1994	
	Zoller, et al., Nucleic Acids Research, Vol. 10, No. 20, p. 6487, 1982	
EXAMINER	/Claire Kaufman/	DATE CONSIDERED
		08/25/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.